公开(公告)号：US20140178332A1

公开(公告)日：2014-06-26

申请号：US14154076

申请日：2014-01-13

Applicant: ABBVIE INC.

Inventor： Susan E. Lacy ,  Emma Fung ,  Jonathan P. Belk ,  Richard W. Dixon ,  Michael Roguska ,  Paul R. Hinton ,  Shankar Kumar

IPC: C07K16/24 ,  A61K39/395 ,  G01N33/68 ,  A61K45/06

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

Abstract translation: 本发明包括IL-12p40结合蛋白，特别是结合人白细胞介素-12（hIL-12）和/或人IL-23（hIL-23）的抗体。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-12和/或hIL-23具有高亲和力，并在体外和体内中和h IL-12和/或hIL-23活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-12和/或hIL-23和用于抑制hIL-12和/或hIL-23活性，例如在患有hIL -12和/或hIL-23活性是有害的。

公开(公告)号：US09670276B2

公开(公告)日：2017-06-06

申请号：US13940506

申请日：2013-07-12

Applicant: AbbVie Inc.

Inventor： Susan E. Lacy ,  Lorenzo Benatuil ,  Meha Chhaya ,  Emma Fung ,  Renee Miller ,  Ravi Chari ,  Sarah J. Heighton ,  Jacqueline G. Bixby

IPC: C12P21/08 ,  A61K39/395 ,  C07K16/24 ,  A61K39/00

CPC classification number: C07K16/245 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: The disclosure provides binding proteins that specifically bind to IL-1α and IL-1β. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1α and/or IL-1β and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation.

公开(公告)号：US20150266977A1

公开(公告)日：2015-09-24

申请号：US14625575

申请日：2015-02-18

Applicant: AbbVie Inc.

Inventor： Chung-Ming Hsieh ,  Alexander Ivanov ,  Wendy Waegell ,  Yulia Kutskova ,  John Memmott ,  Lorenzo Benatuil ,  Jacqueline Bixby ,  Emma Fung ,  Sahana Bose ,  Alyssa Brito

IPC: C07K16/46 ,  C07K16/24 ,  C07K16/22

CPC classification number: C07K16/468 ,  A61K31/353 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/519 ,  A61K31/56 ,  A61K38/13 ,  A61K38/1793 ,  A61K38/18 ,  A61K38/1808 ,  A61K38/1816 ,  A61K38/19 ,  A61K38/191 ,  A61K38/2026 ,  A61K38/2066 ,  A61K38/2073 ,  A61K38/217 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/22 ,  C07K16/241 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/60 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.

Abstract translation: 与用于治疗，预防和诊断硬化性相关疾病的组合物和方法一起描述了结合硬化蛋白或硬化性骨肉瘤和TNF的蛋白质，并用于检测细胞，组织，样品和组合物中的硬化蛋白或硬化性骨肉瘤和TNF。